CancerWorld shared on LinkedIn:
“In Lviv, where hospitals care for patients with devastating injuries and life-threatening infections, clinicians are demonstrating that scientific excellence does not have to wait for peace.
At First Lviv Territorial Medical Union, a randomized Phase 2 trial is investigating an experimental cell therapy for acute respiratory distress syndrome (ARDS), one of critical care’s most challenging conditions.
This is more than a story about a clinical trial. It is about resilience, scientific ambition and the determination to build lasting research capacity in the midst of war.
In CancerWorld, Thiago Favano shares what he discovered in Lviv-and why the experience profoundly changed his understanding of what is possible under extraordinary circumstances.
They came to advance research. They left with a lesson in courage, commitment and humanity.
Read ‘Building a Clinical Trial in a Country at War: What Lviv Taught Us’”
Read more articles about CancerWorld on OncoDaily.